ESR1 and breast carcinoma: Although the combination treatment resulted in a significant reduction in cell growth, this inhibitory effect was attenuated by E2 treatment but strengthened in response to TAM in both ERα-negative breast cancer cell lines, especially in MDA-MB-231 cells.